Page 59 - டாகேடா மருந்து நிறுவனம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Takeda Completes Sale of Select Non-Core Assets to Cheplapharm Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD1. The portfolio includes 16 prescription pharmaceutical products sold predominantly in Europe which is part of Takeda’s Europe and Canada Business Unit. This divestment agreement was first announced in September 2020. The divested portfolio is comprised of non-core prescription pharmaceutical products in a variety of therapeutic categories that includes Cardiovascular/Metabolic and Anti-Inflammatory products along with Calcium. In line with Takeda’s long-term growth strategy, these products, while addressing key patient needs in these countries, are outside of Takeda’s five core business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscien

United statesTakeda europeExchange commissionTakeda pharmaceutical company limitedBlackstone group incAsia pacific to celltrion incTakeda pharmaceutical companyCanada businessRare diseasesPlasma derived therapiesFiscal yearsConsumer healthcare company limitedOscara coBlackstone groupEmerging markets business unitTachosil fibrin sealant patch